论文部分内容阅读
Objective: To study the protective effect of ruanganyin on the liver of HBV transgenic mice. Methods: 50 half HBV transgenic mice, male and female, were randomly divided into treatment group (high, medium and low dose Ruanganyin), model group, positive control group (entecavir dispersible tablet) and 10 non HBV transgenic mice as blank control. The mice were killed after 4 weeks of drug intervention.The serum levels of ALT, AST, TBIL, LN, HA, IV-C and PCIII were observed. Results: (1) compared with the blank control group, the ALT,AST and TBIL levels in the model group were significantly higher than those in the blank control group (P < 0.01); compared with the model group, the ALT, AST and TBIL levels in the high-dose group of ruanganyin after treatment were significantly lower than those in the model group (P<0.01/P<0.05); the ALT, AST and TBIL levels in the positive control group were lower than those in the model group (P<0.01/P<0.05) There was no significant difference in ALT, AST and TBIL levels between the two groups (P>0.05). (2) Compared with the blank control group, the level of LN, HA, IV-C and PCIII in the model group was significantly higher than that in the blank control group (P<0.01); compared with the model group, the level of LN, HA and IV-C in the high-dose group and the positive control group after treatment was significantly lower than that in the model group (P<0.01); the level of PCIII in the high-dose group and the positive control group after treatment was significantly lower than that in the model group (P<0.01); There was no significant difference in LN, HA, IV-C and PCIII levels between the two groups (P> 0.05). Conclusion: Chinese medicine Ruanganyin has the effects of protecting liver, reducing enzyme and anti fibrosis, but its mechanism of anti fibrosis needs further study.